Back to Journals » Therapeutics and Clinical Risk Management » Volume 15

Profile of tezacaftor/ivacaftor combination and its potential in the treatment of cystic fibrosis

Authors Shiferaw D, Faruqi S

Received 17 March 2019

Accepted for publication 16 June 2019

Published 22 August 2019 Volume 2019:15 Pages 1029—1040


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Garry Walsh

Dejene Shiferaw,* Shoaib Faruqi*

Department of Respiratory Medicine, Hull University Teaching Hospitals NHS Trust, Cottingham HU16 5JQ, UK
*These authors contributed equally to this work

Correspondence: Shoaib Faruqi
Department of Respiratory Medicine, University of Hull and Hull and York Medical School, Hull University Teaching Hospitals NHS Trust, Castle Hill Hospital, Castle Road, Cottingham HU16 5JQ, UK
Tel +44 148 262 6706
Email [email protected]

Abstract: Cystic fibrosis (CF) is a life-limiting autosomal recessive disease caused by dysfunction of the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel. Management of CF has traditionally relied upon managing complications of CFTR protein dysfunction and this has led to a steady improvement in survival of CF patients. However, the landscape of CF care has changed substantially over the last decade with the discovery of CFTR modulators that aim to increase or potentially restore the function of the disease-causing CFTR protein. This narrative review summarizes the development of CFTR therapies so far with emphasis on tezacaftor/ivacaftor combination therapy. We have also summarized the Phase II results of triple combination therapy which promises an effective CFTR modulator therapy for more than 90% of CF patients.

Keywords: cystic fibrosis, CFTR modulators, CFTR potentiators, ivacaftor, tezacaftor, triple therapy

Erratum for this paper has been published

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]